Literature DB >> 19168507

Inflammation in chronic heart failure: what is familiar, what is unfamiliar?

Michael Fu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19168507      PMCID： PMC2639414          DOI： 10.1093/eurjhf/hfn039

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  9 in total

1.  TNF-induced cardiomyopathy.

Authors:  S Hegewisch; H J Weh; D K Hossfeld
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

2.  How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.

Authors:  Stefan D Anker; Andrew J S Coats
Journal:  Int J Cardiol       Date:  2002-12       Impact factor: 4.164

Review 3.  Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches.

Authors:  Lars Gullestad; Pål Aukrust
Journal:  Am J Cardiol       Date:  2005-06-06       Impact factor: 2.778

4.  Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death.

Authors:  K A Krown; M T Page; C Nguyen; D Zechner; V Gutierrez; K L Comstock; C C Glembotski; P J Quintana; R A Sabbadini
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

5.  Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial.

Authors:  Guillermo Torre-Amione; Stefan D Anker; Robert C Bourge; Wilson S Colucci; Barry H Greenberg; Per Hildebrandt; Andre Keren; Michael Motro; Lemuel A Moyé; Jan Erik Otterstad; Craig M Pratt; Piotr Ponikowski; Jean Lucien Rouleau; Francois Sestier; Bernhard R Winkelmann; James B Young
Journal:  Lancet       Date:  2008-01-19       Impact factor: 79.321

6.  Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

Authors:  Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

7.  Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.

Authors:  Eugene S Chung; Milton Packer; Kim Hung Lo; Adedigbo A Fasanmade; James T Willerson
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

Review 8.  Immunological mechanisms of pentoxifylline in chronic heart failure.

Authors:  Steven M Shaw; Mohammed K H Shah; Simon G Williams; James E Fildes
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

Review 9.  Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.

Authors:  Stephane Heymans; Emilio Hirsch; Stefan D Anker; Pal Aukrust; Jean-Luc Balligand; Jan W Cohen-Tervaert; Helmut Drexler; Gerasimos Filippatos; Stephan B Felix; Lars Gullestad; Denise Hilfiker-Kleiner; Stefan Janssens; Roberto Latini; Gitte Neubauer; Walter J Paulus; Burkert Pieske; Piotr Ponikowski; Blanche Schroen; Heinz-Peter Schultheiss; Carsten Tschöpe; Marc Van Bilsen; Faiez Zannad; John McMurray; Ajay M Shah
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534
  9 in total
  5 in total

Review 1.  Muscle atrophy in aging and chronic diseases: is it sarcopenia or cachexia?

Authors:  Maurizio Muscaritoli; Simone Lucia; Alessio Molfino; Tommy Cederholm; Filippo Rossi Fanelli
Journal:  Intern Emerg Med       Date:  2012-07-08       Impact factor: 3.397

2.  Determinants of exercise capacity in dilated cardiomyopathy: a prospective, explorative cohort study.

Authors:  Wilhelm Grander; Bernhard Koller; Johannes Schwaiger; Herbert Tilg; Martin W Dünser
Journal:  Wien Klin Wochenschr       Date:  2012-08-10       Impact factor: 1.704

3.  Distinct roles of resident and nonresident macrophages in nonischemic cardiomyopathy.

Authors:  Xudong Liao; Yuyan Shen; Rongli Zhang; Keiki Sugi; Neelakantan T Vasudevan; M Amer Alaiti; David R Sweet; Lin Zhou; Yulan Qing; Stanton L Gerson; Chen Fu; Anthony Wynshaw-Boris; Rui Hu; Martin A Schwartz; Hisashi Fujioka; Brian Richardson; Mark J Cameron; Hiroki Hayashi; Jonathan S Stamler; Mukesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-30       Impact factor: 11.205

Review 4.  Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results.

Authors:  Timea Magdolna Szabo; Attila Frigy; Előd Ernő Nagy
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

Review 5.  Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy.

Authors:  Larisa Anghel; Radu Sascău; Ioana Mădălina Zota; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.